|Description||TACI, a member of the TNF Receptor superfamily, is expressed in the small intestine, spleen, thymus, peripheral blood leukocytes, activated T cells, and resting B cells. TACI binds to both APRIL and BAFF and can stimulate the activation of transcription factors; NF-kappaB, AP-1, and mediates calcineurin dependent activation of NF-AT (nuclear-factor of activated T cells). TACI also plays a key role in the stimulation of B and T cell function. Soluble TACI inhibits APRIL-stimulated proliferation of primary B-cells by blocking the binding of APRIL to the membrane anchored TACI receptor. Recombinant human TACI is a soluble 159 amino acid polypeptide (17.8 kDa) comprising the TNFR homologous cysteine rich extracellular domain of the TACI protein.|
|BiologicalActivity||Determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0-3.0 µg/ml.|
|Authenticity||Verified by N-terminal and Mass Spectrometry analyses (when applicable).|
|Endotoxin||Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg).|
|Protein Content||Verified by UV Spectroscopy and/or SDS-PAGE gel.|
|Precautions||Recombinant Human TACI (TNFRSF13B) is for research use only and not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.